Loading data for ATRA — first visit, this takes a few seconds.

アラート

Atara Biotherapeutics Inc... (ATRA)

NasdaqGS: ATRA · リアルタイム株価 · USD

9.20

-0.05 (-0.54%)

終値時点： Aug 28, 2026, 3:59 PM

9.20

+0.00%

時間外: 7:30 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-0.54% (1D)

買気配	6.58
時価総額	92.35M
売上高（TTM）	6.19M
純利益（TTM）	-16.69M
	0.10
	-1.54
	n/a
	5.88
PBR（TTM）	-2.35
PSR（TTM）	14.91
決算発表日	Nov 12, 2026

売気配	11.69
出来高	15,345
平均出来高（20日）	70,195
始値	9.18
前日終値	9.25
当日レンジ	8.90 - 9.21
52週レンジ	3.92 - 19.14
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

ATRAについて

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, ...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Oct 16, 2014

従業員数 10

上場取引所 NasdaqGS

ティッカー ATRA

ウェブサイト https://www.atarabio.com

企業情報の全文

業績

2025年のAtara Biotherapeuticsの売上高は120.77Mで、前年の128.94Mから-6.33%の減少でした。利益は32.69Mで、-138.28%の減少でした。

財務諸表

決算サプライズ

Atara BiotherapeuticsはAug 12, 2026に四半期決算を発表しました：

売上高は $516K で、予想を下回りました $0, うち -99.47% の前年比減少.
EPSは -0.32 で、予想を下回りました -0.07, うち -109.14% の前年比減少.

次回決算発表

Atara Biotherapeutics Inc.の決算発表予定日は Nov 12, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2か月前 · Investor's Business Daily

Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End

Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.

3か月前 · Zacks

ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know

Atara stock soars 82% as the FDA outlines a regulatory pathway for its lead product candidate, tab-cel, reviving hopes for potential U.S. approval, after two prior CRLs.

3か月前 · InvestorsHub

FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive

Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the tabelecleucel application after a recent Complete Response Letter. Key Investor TakeawaysAtara Biotherapeutics (NAS...

4か月前 · Insider Monkey

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise

We recently compiled a list of the 10 Best Cheap Stocks Under $10 to Buy in April. Atara Biotherapeutics, Inc. is among the best cheap stocks to buy. TheFly reported on March 17 that ATRA filed a pros...

5か月前 · Associated Press Finance

Atara Biotherapeutics: Q4 Earnings Snapshot

ATRA) on Monday reported a loss of $3.4 million in its fourth quarter. The Thousand Oaks, California-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $1.6 m...

2ページ中1ページ

Atara Biotherapeutics Inc... (ATRA)